Floatz logo

Cilengitide

Recurrent Marginal Zone Lymphoma

National Cancer Institute (NCI)protein_peptidePhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

106 Active assets in the Recurrent Marginal Zone Lymphoma cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
University of Miami
Phase 2BBB
Fludarabine
Paolo Caimi, MD
Phase 2BBB
Orelabrutinib
Henan Cancer Hospital
Phase 4BBB
FILGRASTIM
Fred Hutchinson Cancer Center
Phase 2BBB
VINCRISTINE SULFATE
Mayo Clinic
Phase 2BBB

View all 50 →

Same molecule, other indications

Cilengitide is also rated in:

adult glioblastomaDormant
B
Indicative ·
61 / 100
View asset →
gliosarcomaDormant
B
Indicative ·
61 / 100
View asset →
giant cell glioblastomaDormant
B
Indicative ·
61 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →